Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial.
Yoshiya TanakaKoji ObaTakao KoikeNobuyuki MiyasakaTsuneyo MimoriTsutomu TakeuchiShintaro HirataEiichi TanakaHidekata YasuokaYuko KanekoKosaku MurakamiTomohiro KogaKazuhisa NakanoKoichi AmanoKazuyasu UshioTatsuya AtsumiMasayuki InooKazuhiro HattaShinichi MizukiShouhei NagaokaShinichiro TsunodaHiroaki DobashiNao HorieNorihiro SatoPublished in: Annals of the rheumatic diseases (2019)
Programmed treatment strategy did not statistically increase the sustained remission rate after 1 year discontinuation of IFX treatment.